1-10 of 10
Ellen Nong Wei
Close
Sort by
Journal Articles

Selective Cell State in the Clonally Expanded T-Cell Compartment of Vκ*MYC Mice Responding to Treatment with Checkpoint Inhibitors

Danielle C Croucher, Laura M Richards, Zhihua Li, Ellen nong Wei, Xian Fang Huang, Daniel Waller, Marta Chesi, P. Leif Bergsagel, Michael Sebag, Trevor J. Pugh, Suzanne Trudel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1581.
https://doi.org/10.1182/blood-2021-151242
Published: 2021
Journal Articles

Disrupting Mitohormesis As a Novel Therapeutic Strategy for Multiple Myeloma (MM) Including Those with High Risk Disease and Proteosome Inhibitor Resistance

Serges P Tsofack, Danielle C Croucher, Benjamin G Barwick, Zhihua Li, Ahmed Aman, Dennis Tao, Ellen nong Wei, Laura Garcia Prat, Aaron D Schimmer, Suzanne Trudel
Journal: Blood
Blood (2021) 138 (Supplement 1): 722.
https://doi.org/10.1182/blood-2021-148673
Published: 2021
Journal Articles

Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium

Suzanne Trudel, MD, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Annette E Hay, MB ChB, Olena Kis, PhD, Signy Chow, MD FRCPC, Zhi Hua Li, MD, Ellen Nong Wei, MSc, Lisa Wang, PhD, Christine Tran, Smitha Udagani, Chantale Blattler, Trevor J. Pugh, PhD, Helen X Chen, MD, Amit Oza, MD
Journal: Blood
Blood (2016) 128 (22): 4526.
https://doi.org/10.1182/blood.V128.22.4526.4526
Published: 2016
Journal Articles

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Harminder Paul, Susi Snitzler, RN, Lisa W Le, MSc, Ellen Nong Wei, Anthea Lau, James B Johnston, MD, Spencer B. Gibson, PhD, Michelle L. Queau, B.Sc, Suzanne Trudel, MD
Journal: Blood
Blood (2015) 126 (23): 4163.
https://doi.org/10.1182/blood.V126.23.4163.4163
Published: 2015
Journal Articles

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Susi Snitzler, RN, Olga Levina, RN, Tong (Trina) Wang, RN, Lisa W Le, MSc, Harminder Paul, Ellen Nong Wei, Anthea Lau, Michelle Queau, James B Johnston, MD, Suzanne Trudel, MD, Deborah A Smith
Journal: Blood
Blood (2015) 126 (23): 1742.
https://doi.org/10.1182/blood.V126.23.1742.1742
Published: 2015
Journal Articles

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Christine I. Chen, MD, Susi Snitzler, RN, Trina Wang, RN, Harminder Paul, Lisa W Le, Ellen Nong Wei, MSc, Anthea Lau, Deborah A Smith, PharmD, Michelle Brown, James B Johnston, MD, Suzanne Trudel, MD, MSC, FRCPC
Journal: Blood
Blood (2013) 122 (21): 4175.
https://doi.org/10.1182/blood.V122.21.4175.4175
Published: 2013
Journal Articles

A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma

Danielle C Croucher, MSc, BSc, Zhihua Li, Brent D.G. Page, PhD, Ellen Nong Wei, Patrick T. Gunning, PhD, Suzanne Trudel, MD, MSC, FRCPC
Journal: Blood
Blood (2013) 122 (21): 4441.
https://doi.org/10.1182/blood.V122.21.4441.4441
Published: 2013
Journal Articles

GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL

Suzanne Trudel, MD, Sam Scanga, PhD, Fabrizio G Mastronardi, PhD, Ellen Nong Wei, MSc, Frank Mercurio, PhD, Antonia Lopez-Girona, PhD, Svetlana Gaidarova, MS, David R. Webb, PhD, Christine Chen, MD, Keith Stewart, MBA, MB, CHB, Armen S Manoukian, PhD
Journal: Blood
Blood (2012) 120 (21): 1793.
https://doi.org/10.1182/blood.V120.21.1793.1793
Published: 2012
Journal Articles

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

Christine Chen, MD, Harminder Paul, Trina Wang, RN, Lisa W Le, MSc, Vishal Kukreti, MD, Ellen Nong Wei, Anthea Lau, P. Leif Bergsagel, MD, Nimisha Dave, Suzanne Trudel, MD
Journal: Blood
Blood (2012) 120 (21): 718.
https://doi.org/10.1182/blood.V120.21.718.718
Published: 2012
Journal Articles

An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Christine Chen, MD, Harminder Paul, Luisa Del Rizzo, Lisa W Le, MSc, Ellen Nong Wei, Anthea Lau, James B Johnston, MD, Spencer B Gibson, PhD, Michelle Brown, Suzanne Trudel, MD
Journal: Blood
Blood (2012) 120 (21): 2895.
https://doi.org/10.1182/blood.V120.21.2895.2895
Published: 2012